Related references
Note: Only part of the references are listed.Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Li Shen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
S100A9 Interaction with TLR4 Promotes Tumor Growth
Eva Kallberg et al.
PLOS ONE (2012)
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Roberto Pili et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antigen specificity of immune suppression by myeloid-derived suppressor cells
Samantha Solito et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Cesar A. Corzo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Per Bjork et al.
PLOS BIOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
Pingyan Cheng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2008)
Altered macrophage differentiation and immune dysfunction in tumor development
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Share Paper
